Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review
BackgroundEmicizumab, a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis of bleeding episodes in people with hemophilia A, can impose a significant financial burden. We conducted a systematic review to evaluate the reporting quality of existing pharmacoeconomic...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-10-01
|
| Series: | Frontiers in Public Health |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1658760/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|